Evidence map›Paper›PMID 30094499›Full record

SynthesisNeurosurgical review2020

Depression and glioblastoma, complicated concomitant diseases: a systemic review of published literature.

Luke Mugge, Tarek R Mansour, Megan Crippen, Yasaman Alam, Jason Schroeder

Registry-linked trialAbstract readSystematic Review
PubMed Publisher
In one paragraph

Synthesis in Neurosurgical review, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07409584 (Mental Health and Suicidality in Glioblastoma Patients in Germany - a Multicenter Observational Study), which is not on this map. Cited by 33 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed, 1 pooled it
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07409584 recruitingnot on this mapstarted 2026, after this paper: background citation

Mental Health and Suicidality in Glioblastoma Patients in Germany - a Multicenter Observational Study (SHINE-GLIO Study)

TypeobservationalSponsorUniversity Hospital, EssenRan2026 to 2028Enrolled180ConditionsGlioblastoma (GBM)ArmsMedical history, physical examination, completing questionnaires, data collection
3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 1 synthesis or guideline pooled it, 58 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Observational
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Depression in brain tumor patients-early detection and screening.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2023
    Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Luke MuggeDepartment of Neurosurgery, The University of Toledo Medical Center, 3000 Arlington Ave, Toledo, OH, 43614, USA. luke.mugge@utoledo.edu.ORCID http://orcid.org/0000-0003-1749-2745
Tarek R MansourDepartment of Neurosurgery, The University of Toledo Medical Center, 3000 Arlington Ave, Toledo, OH, 43614, USA.
Megan CrippenDepartment of Neurosurgery, The University of Toledo Medical Center, 3000 Arlington Ave, Toledo, OH, 43614, USA.
Yasaman AlamDepartment of Neurosurgery, The University of Toledo Medical Center, 3000 Arlington Ave, Toledo, OH, 43614, USA.
Jason SchroederDepartment of Neurosurgery, The University of Toledo Medical Center, 3000 Arlington Ave, Toledo, OH, 43614, USA.
University of Toledo Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Glioblastoma multiforme (GBM) is the most common primary brain cancer. Depression is a common co-morbidity of this condition. Despite this common interaction, relatively little research has been performed on the development of GBM-associated depression. We performed a literary search of the PubMed database for articles published relating to GBM and depression. A total of 85 articles were identified with 46 meeting inclusion criteria. Depression significantly impacts care, decreasing medication compliance, and patient survival. Diagnostically, because depression and GBM share intricate neuro-connectivity in a way that effect functionality, these diseases can be mistaken for alternative psychological or pathological disorders, complicating care. Therapeutically, anti-depressants have anti-tumor properties; yet, some have been shown to interfere with GBM treatment. One reason for this is that the pathophysiological development of depression and GBM share several pathways including altered regulation of the 5-HT receptor, norepinephrine, and 3':5'-cyclic monophosphate. Over time, depression can persist after GBM treatment, affecting patient quality of life. Together, depression and GBM are complicated concomitant diseases. Clinicians must be aware of their co-existence. Because of overlapping molecular pathways involved in both diseases, careful medication selection is imperative to avoid potential adverse interactions. Since GBMs are the most common primary brain cancer, physicians dealing with this disease should be prepared for the development of depression as a potential sequela of this condition, given the related pathophysiology and the known poor outcomes.

Indexed as

Antidepressive AgentsBrain NeoplasmsGlioblastomaHumansMajor Depressive DisorderQuality of LifeAntidepressive AgentsAnti-depressantsDepressionGlioblastomaMajor depressive disorderPatient outcomes

Identifiers

PMID30094499
OpenAlexW2887157722

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.